Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Operating Income (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Operating Income for 8 consecutive years, with -$20.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Income rose 2.86% to -$20.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$89.5 million, a 452.28% decrease, with the full-year FY2024 number at -$26.2 million, up 40.18% from a year prior.
  • Operating Income was -$20.7 million for Q3 2025 at Precision Biosciences, up from -$21.9 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $24.1 million in Q2 2024 to a low of -$30.7 million in Q4 2021.
  • A 5-year average of -$12.0 million and a median of -$14.9 million in 2023 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: surged 871.68% in 2024, then plummeted 428.11% in 2025.
  • Precision Biosciences' Operating Income stood at -$30.7 million in 2021, then surged by 157.18% to $17.6 million in 2022, then tumbled by 184.75% to -$14.9 million in 2023, then plummeted by 66.86% to -$24.8 million in 2024, then rose by 16.82% to -$20.7 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Operating Income are -$20.7 million (Q3 2025), -$21.9 million (Q2 2025), and -$22.1 million (Q1 2025).